Australia: Shares in medical cannabis company MMJ PhytoTech are tanking

Warning message

The subscription service is currently unavailable. Please try again later.

Shares in MMJ PhytoTech dropped sharply after the medical cannabis company announced a first half loss and a successful $5 million equity capital raising.

A short time ago, the shares were down 14.7% to $0.29.

The company is issuing 20,833,333 shares at 24 cents each, a 20% discount to the 15 day average price.

The funds raised will be used to accelerate the company’s entry into the Australian market following the passing of legislation by the federal government legalising cannabis for medicinal purposes.

The funding will also be applied for a phase two clinical study to further test an oral capsule for treating multiple sclerosis.

The company posted a $3.48 million loss for the six months to December. Revenue was $274,000. 

Last year Phytotech merged with Canadian company MMJ Bioscience to create a “farm to pharma” global strategy, growing and processing cannabis to create new products.

Since then, the company has...

Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.